Genentech Submits Biologics License Application for FDA Review of Lucentis(TM) in Wet Age-Related Macular Degeneration

Genentech, Inc. (NYSE: DNA) announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of Lucentis(TM) (ranibizumab) in the treatment of neovascular wet age-related macular degeneration (AMD). Lucentis is the first therapy for wet AMD to have shown improved vision in two pivotal Phase III trials and demonstrated a clinical benefit over verteporfin (Visudyne(R)) photodynamic therapy (PDT) in a head-to-head clinical trial. As part of the Lucentis BLA submission, Genentech has requested a Priority Review designation from the FDA, which, if granted, would give the FDA six months from the Agency's receipt of the submission to take action on the application.

The BLA submission is based on one-year clinical data on the efficacy and safety of Lucentis from two pivotal Phase III trials, ANCHOR and MARINA, as well as one-year clinical data from the Phase I/II FOCUS trial. In addition to these registrational studies, Genentech is currently enrolling patients with wet AMD in a Phase IIIb safety study called SAILOR. Data from the Phase IIIb PIER study evaluating a less frequent dosing regimen for Lucentis are anticipated in the first half of 2006.

"This application represents a summary of data from more than six years of rigorous clinical study and the dedication of thousands of patients and physicians hoping to improve outcomes for those with this devastating disease," said Hal Barron, M.D., Genentech's senior vice president of Development and chief medical officer. "We look forward to working with the FDA in our efforts to bring this potential therapy to patients quickly as it may offer benefit to patients with all types of wet AMD."

ANCHOR

Author:  

Email:    

Topic:    

Content:

Related Computer Hardware Articles

• Northwest Disappointed and Surprised by U.S. DOT's Denial of SkyTeam Airlines' Anti-Trust Immunity Application
  25 December 2005



• SellMasters Announces Availability of Sales Opportunity Snapshot (SOS) Workshop and Companion Application
  8 December 2005



• Intentia Links with Vision Solutions Adds Database Archiving System for Intentia Application Suite
  29 November 2005



• Case Western Reserve University Selects Virage's Core Technology to Power its MediaVision Application
  24 November 2005



• Cenzic Research Lab Names Top Five Critical Web Application Vulnerabilities for October
  24 November 2005



• Paraxip Software to be Featured in Intel VoIP Application Development Platform
  16 November 2005



• Compuware Helps Accelerate Development, Improve Application Quality With New Versions of DevPartner Products for Microsoft Visual Studio 2005
  9 November 2005



• Compuware Extends Leadership Position in Ensuring Outstanding End-user Experience With Enhanced Application Service Management Solutions
  1 November 2005



• FUN Technologies' SkillJam mobile skill-gaming application,
  22 October 2005



• Fairchild Semiconductor Deploys Advantest Tester for Wafer-Probe Application
  19 October 2005